EKF Diagnostics Holdings Plc

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB0031509804
GBP
0.25
0.01 (4.17%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About EKF Diagnostics Holdings Plc stock-summary
stock-summary
EKF Diagnostics Holdings Plc
Pharmaceuticals & Biotechnology
EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. The Company's Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen C-Line and Biosen S-Line, STAT-Site M B-HB analyzer, sTNFR1 biomarker test kits and Altair 240.
Company Coordinates stock-summary
Company Details
Avon HSE, 19 Stanwell Road , PENARTH None : CF64 2EZ
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Christopher Mills
Non-Executive Chairman of the Board
Mr. Julian Baines
Chief Executive Officer, Executive Director
Mr. Richard Evans
Finance Director, Chief Operating Officer, Executive Director
Mr. Carl Contadini
Non-Executive Independent Director
Mr. Adam Reynolds
Senior Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 106 Million (Small Cap)

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.23

stock-summary
Return on Equity

9.53%

stock-summary
Price to Book

1.48